{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:23:13Z","timestamp":1776914593521,"version":"3.51.2"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/jcp.0b013e318160864f","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T06:33:54Z","timestamp":1236234834000},"page":"69-73","source":"Crossref","is-referenced-by-count":39,"title":["Reduction in Neuroleptic-Induced Movement Disorders After a Switch to Quetiapine in Patients With Schizophrenia"],"prefix":"10.1097","volume":"28","author":[{"given":"Leonardo","family":"Cortese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Caligiuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schieldrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Malla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Harricharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analyses.","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function.","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v59n0906","article-title":"Clozapine withdrawal-emergent dystonias and dyskinesias: a case series.","volume":"59","author":"Ahmed","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0278-5846(99)00095-0","article-title":"Switching outpatients between atypical antipsychotics.","volume":"24","author":"Bogan","year":"2000","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Seroquel Trial 13 Study Group. Multiple fixed dosed of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia compared with haloperidol and placebo.","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.jcp.0000084034.22282.78","article-title":"Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia.","volume":"23","author":"Tandon","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4088\/JCP.v60n0504","article-title":"Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders.","volume":"60","author":"McManus","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00004850-200209000-00006","article-title":"Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia.","volume":"17","author":"Alptekin","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"R9-12-20210128","first-page":"1","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia.","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia.","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199908000-00007","article-title":"Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics.","volume":"19","author":"Caligiuri","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002130050320","article-title":"Reliability of instrumental assessment of tardive dyskinesia: results from VA co-operative study 394.","volume":"32","author":"Caligiuri","year":"1997","journal-title":"Psychopharmacology"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/jnp.2.4.395","article-title":"Fine force instability: a quantitative measure of hand dyskinesia.","volume":"2","author":"Caligiuri","year":"1990","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/1469-8986.3540431","article-title":"Scaling of movement velocity: a measure of neuromotor retardation in individuals with psychopathology.","volume":"35","author":"Caligiuri","year":"1998","journal-title":"Psychophysiology"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199202000-00001","article-title":"Quantifying drug-induced changes in parkinsonian rigidity using an instrumental measure of activated stiffness.","volume":"15","author":"Caligiuri","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0269881105056668","article-title":"Switching antipsychotic: an updated review with a focus on quetiapine.","volume":"20","author":"Weiden","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.schbul.a006920","article-title":"Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.","volume":"28","author":"Covell","year":"2002","journal-title":"Schizophr Bull"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications.","volume":"163","author":"Essock","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study.","volume":"11","author":"Gefvert","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia.","volume":"161","author":"Marder","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13651500310001095","article-title":"Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics.","volume":"7","author":"De Nayer","year":"2003","journal-title":"Int J Psychiatry Clin Pract"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200802000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:36:56Z","timestamp":1618277816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200802000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318160864f","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}